Malopolskie Centrum Kliniczne

The trials here

What the 36 trials at this site are about, from their registry records.

Conditions

• Psoriatic arthritis7 trials
• Psoriasis5 trials
• Rheumatoid arthritis4 trials
• Sjögren's disease4 trials
• Systemic sclerosis (scleroderma)4 trials
• Atopic dermatitis (eczema)3 trials
• COPD2 trials
• Crohn's disease2 trials
• Dermatomyositis and polymyositis (myositis)2 trials
• Vitiligo2 trials
• Ankylosing spondylitis1 trial
• Gout1 trial
• and 6 more

Phase

• Phase 322 trials
• Phase 28 trials
• Phase 14 trials
• Phase 42 trials

Status

• Completed13 trials
• Active, not recruiting11 trials
• Not yet recruiting6 trials
• Recruiting5 trials
• Withdrawn1 trial

Lead sponsor

• AbbVie7 trials
• Cullinan Therapeutics Inc.3 trials
• Horizon Therapeutics Ireland Designated Activity Company3 trials
• MoonLake Immunotherapeutics AG3 trials
• Amgen2 trials
• and 16 more

Running trials

• Recruiting

  A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo

  NCT07667569· Phase 2· Idorsia Pharmaceuticals Ltd.· Source

• Recruiting

  A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  NCT07564414· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

  2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Recruiting

  A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

  NCT07047690· Phase 2· Galderma R&D· Source

• Recruiting

  Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis

  NCT07235904· Phase 4· University Hospital Schleswig-Holstein· Source

• Recruiting

  A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease

  2025-521462-96-00· Phase 1· Cullinan Therapeutics Inc.· Source

• Recruiting

  A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

  NCT06972446· Phase 2· AbbVie· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

  NCT07037901· Phase 2· Inmagene LLC· Source

• Recruiting

  A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA)

  2024-519114-31-00· Phase 1· Cullinan Therapeutics Inc.· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.

  2024-516219-25-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Recruiting

  A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

  NCT06747949· Phase 3· Amgen· Source

• Active, not recruiting

  Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

  NCT06843239· Phase 2· Zura Bio Inc· Source

• Recruiting

  A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

  NCT06698796· Phase 3· Pfizer· Source

• Recruiting

  A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

  NCT06613360· Phase 1· Cullinan Therapeutics Inc.· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· AbbVie· Source

• Active, not recruiting

  A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

  NCT06118411· Phase 3· AbbVie· Source

• Recruiting

  A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

  NCT05895786· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

  NCT04908202· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

  NCT03675308· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

  NCT03671148· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

  NCT02629159· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Dermatomyositis and polymyositis (myositis)2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Crohn's disease1 recruiting
• Lupus (SLE)1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Ulcerative colitis1 recruiting
• Vitiligo1 recruiting

Closed trials

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07690371· Phase 3· Nektar Therapeutics· Source

• Completed

  A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis

  2023-506664-14-00· Phase 3· Dr Reddy's Laboratories Limited· Source

• Completed

  A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome

  2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis

  2022-502997-18-00· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Completed

  Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLANE

  2023-505050-18-00· Phase 4· Charite Universitaetsmedizin Berlin KöR· Source

• Terminated

  Hidradenitis Suppurativa Study of Izokibep

  NCT05905783· Phase 3· ACELYRIN Inc.· Source

• Completed

  Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

  NCT05586971· Phase 3· LG Chem· Source

• Completed

  A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

  NCT04781543· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

  NCT04320342· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

  2023-509782-20-00· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

  NCT04936308· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

  NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Active, not recruiting

  A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

  NCT03345823· Phase 3· AbbVie· Source